Gladstone NOW: The Campaign Join Us on the Journey ✕
46 - 60 of 118 Results Clear All
A unique combination of expertise at Gladstone Institutes and UC San Francisco will enable new therapies for Alzheimer’s disease and multiple sclerosis
Institutional News News Release Multiple Sclerosis Alzheimer’s Disease Akassoglou Lab
The philanthropic gift will support cross-disciplinary research to find novel treatments for multiple neurological diseases
Donor Stories Multiple Sclerosis Alzheimer’s Disease Akassoglou Lab
An expert from Gladstone Institutes helps shape the new recommendations
Office of the Chief Operating Officer Gladstone Experts Institutional News Alzheimer’s Disease
The cells constantly survey the brain to prevent spontaneous seizures, Gladstone scientists discover
News Release Research (Publication) Multiple Sclerosis Alzheimer’s Disease Neurological Disease Akassoglou Lab Palop Lab Imaging
Long-time Gladstone supporter helps scientists pursue Alzheimer’s disease research
Donor Stories Alzheimer’s Disease
The Dolby family has supported Gladstone research since 2015
Donor Stories Alzheimer’s Disease
The 2020 Berkelhammer Scholars break new ground in research on dementias, Parkinson’s disease, and neuropsychiatric disorders
Donor Stories Parkinson’s Disease Alzheimer’s Disease Dementia Neurological Disease Akassoglou Lab Kreitzer Lab Mahley Lab Mucke Lab Nakamura Lab
San Francisco Business Times—Gabaeron, founded by Gladstone President Emeritus Bob Mahley, MD, PhD, and Therini Bio (formerly Medared), founded upon work by Senior Investigator Katarina Akassoglou, PhD, are among Bay Area biotech companies focusing on neurological diseases that collectively raised more than $3 billion from venture capital firms and the public capital markets in 2020.
Gladstone Experts Parkinson’s Disease Multiple Sclerosis Alzheimer’s Disease Neurological Disease Akassoglou Lab Mahley Lab
Drug Target Review—Senior Investigator Katerina Akassoglou, PhD, explains her team’s recent discovery of the immune cells in the brain that promote neurodegeneration in diseases such as multiple sclerosis and Alzheimer’s disease.
Gladstone Experts Multiple Sclerosis Alzheimer’s Disease Neurological Disease Akassoglou Lab
A new lab to study the impact of lived experiences on developing Alzheimer’s disease
Institutional News News Release Profile Alzheimer’s Disease Data Science and Biotechnology Neurological Disease Corces Lab Aging
With an estimated 44 million diagnosed with Alzheimer’s disease worldwide, research is moving quickly to better understand the disease.
Gladstone Experts Alzheimer’s Disease Neurological Disease Mahley Lab Mucke Lab
ImmunoFrontiers—Senior Investigator Katerina Akassoglou, PhD, describes her lab's recent discovery of the genetic mechanisms that drive brain inflammation in neurodegenerative diseases.
Gladstone Experts Parkinson’s Disease Multiple Sclerosis Alzheimer’s Disease Neurological Disease Akassoglou Lab
New study shows reducing levels of the protein tau prevents core autism symptoms in animal models
News Release Research (Publication) Behavioral Core Histology and Light Microscopy Core Alzheimer’s Disease Neurological Disease Mucke Lab
With $4.8 million from the NIH, Gladstone scientists will investigate how the protein apoE4 causes neurodegeneration in Alzheimer’s disease.
Grants News Release Alzheimer’s Disease Neurological Disease Krogan Lab Mahley Lab
New study shows potentiating a subset of NMDA receptors may be beneficial in Alzheimer’s disease and Dravet syndrome.
News Release Research (Publication) Alzheimer’s Disease Epilepsy Neurological Disease Palop Lab
